CureVac Earns Repeat Recognition by LexisNexis(R) as One of the World’s Top Innovators
CureVac (Nasdaq: CVAC) has been recognized as a Top 100 Global Innovator by LexisNexis® for the third consecutive year (2023-2025), highlighting its dynamic innovation and extensive intellectual property portfolio in mRNA technology. The recognition is based on the company's patent portfolio quality and advancement, evaluated through the Innovation Momentum methodology and Patent Asset Index.
As a pioneer in mRNA therapeutics, CureVac has developed proprietary foundational technologies over 25 years in mRNA design, delivery, and manufacturing. The company maintains one of the field's most comprehensive patent portfolios, with approximately 1,000 issued patents covering mRNA technology, manufacturing, and mRNA-based vaccines and therapies. These innovations have contributed significantly to COVID-19 vaccine development and other medical advances.
CureVac (Nasdaq: CVAC) è stata riconosciuta come una Top 100 Global Innovator da LexisNexis® per il terzo anno consecutivo (2023-2025), evidenziando la sua innovazione dinamica e un ampio portafoglio di proprietà intellettuale nella tecnologia mRNA. Il riconoscimento si basa sulla qualità e sul progresso del portafoglio brevetti dell'azienda, valutati attraverso la metodologia Innovation Momentum e il Patent Asset Index.
In qualità di pioniere nella terapia mRNA, CureVac ha sviluppato tecnologie fondamentali proprietarie in oltre 25 anni di progettazione, distribuzione e produzione di mRNA. L'azienda mantiene uno dei portafogli di brevetti più completi del settore, con circa 1.000 brevetti concessi che coprono la tecnologia mRNA, la produzione e i vaccini e terapie a base di mRNA. Queste innovazioni hanno contribuito in modo significativo allo sviluppo del vaccino COVID-19 e ad altri progressi medici.
CureVac (Nasdaq: CVAC) ha sido reconocida como una Top 100 Global Innovator por LexisNexis® por tercer año consecutivo (2023-2025), destacando su innovación dinámica y su extenso portafolio de propiedad intelectual en tecnología de mRNA. El reconocimiento se basa en la calidad y el avance del portafolio de patentes de la empresa, evaluados a través de la metodología Innovation Momentum y el Patent Asset Index.
Como pionera en terapias de mRNA, CureVac ha desarrollado tecnologías fundamentales propietarias a lo largo de 25 años en diseño, entrega y fabricación de mRNA. La empresa mantiene uno de los portafolios de patentes más completos del campo, con aproximadamente 1.000 patentes otorgadas que abarcan tecnología de mRNA, fabricación y vacunas y terapias basadas en mRNA. Estas innovaciones han contribuido significativamente al desarrollo de la vacuna COVID-19 y a otros avances médicos.
CureVac (Nasdaq: CVAC)는 LexisNexis®에 의해 Top 100 Global Innovator로 세 번째 연속 선정되었습니다 (2023-2025). 이는 mRNA 기술에서의 역동적인 혁신과 광범위한 지적 재산 포트폴리오를 강조합니다. 이 인정은 회사의 특허 포트폴리오의 품질과 발전에 기반하여 Innovation Momentum 방법론과 Patent Asset Index를 통해 평가됩니다.
mRNA 치료제의 선구자로서 CureVac는 mRNA 설계, 전달 및 제조 분야에서 25년 이상에 걸쳐 독점적인 기초 기술을 개발해왔습니다. 이 회사는 mRNA 기술, 제조, mRNA 기반 백신 및 치료를 포함하는 약 1,000개의 발급된 특허를 보유하고 있어 이 분야에서 가장 포괄적인 특허 포트폴리오 중 하나를 유지하고 있습니다. 이러한 혁신은 COVID-19 백신 개발 및 기타 의료 발전에 크게 기여했습니다.
CureVac (Nasdaq: CVAC) a été reconnue comme un Top 100 Global Innovator par LexisNexis® pour la troisième année consécutive (2023-2025), soulignant son innovation dynamique et son vaste portefeuille de propriété intellectuelle dans la technologie mRNA. Cette reconnaissance repose sur la qualité et l'avancement du portefeuille de brevets de l'entreprise, évalués à travers la méthodologie Innovation Momentum et le Patent Asset Index.
En tant que pionnière dans les thérapies mRNA, CureVac a développé des technologies fondamentales propriétaires au cours de 25 années de conception, de livraison et de fabrication de mRNA. L'entreprise maintient l'un des portefeuilles de brevets les plus complets du secteur, avec environ 1.000 brevets délivrés couvrant la technologie mRNA, la fabrication et les vaccins et thérapies à base de mRNA. Ces innovations ont contribué de manière significative au développement du vaccin COVID-19 et à d'autres avancées médicales.
CureVac (Nasdaq: CVAC) wurde von LexisNexis® zum dritten Mal in Folge (2023-2025) als Top 100 Global Innovator ausgezeichnet, was ihre dynamische Innovation und ihr umfangreiches Portfolio an geistigem Eigentum in der mRNA-Technologie hervorhebt. Die Auszeichnung basiert auf der Qualität und dem Fortschritt des Patentportfolios des Unternehmens, das durch die Innovation Momentum-Methode und den Patent Asset Index bewertet wurde.
Als Pionier in der mRNA-Therapie hat CureVac über 25 Jahre hinweg proprietäre grundlegende Technologien in der mRNA-Entwicklung, -Lieferung und -Herstellung entwickelt. Das Unternehmen verfügt über eines der umfassendsten Patentportfolios auf diesem Gebiet, mit etwa 1.000 erteilten Patenten, die mRNA-Technologie, Herstellung und mRNA-basierte Impfstoffe und Therapien abdecken. Diese Innovationen haben erheblich zur Entwicklung des COVID-19-Impfstoffs und anderen medizinischen Fortschritten beigetragen.
- Recognition as Top 100 Global Innovator for third consecutive year
- Holds approximately 1,000 issued patents in mRNA technology
- Maintains one of the broadest patent portfolios in the mRNA field
- None.
Insights
While industry accolades often carry weight for investors, CureVac's intellectual property position deserves careful analysis. Their portfolio of approximately 1,000 issued patents represents a significant strategic asset in the highly competitive mRNA field, particularly given their foundational work in mRNA design, delivery, and manufacturing.
The company's current market capitalization of
- Licensing opportunities with other mRNA companies developing therapeutics and vaccines
- Strategic partnerships leveraging their proprietary technology platform
- Potential patent enforcement actions to monetize their IP
- Defensive value against competitors in the mRNA space
The LexisNexis recognition, based on the Patent Asset Index methodology, specifically highlights the quality and future potential of CureVac's patents. This is particularly relevant as the mRNA field continues to expand beyond vaccines into therapeutics for various diseases, potentially increasing the value of foundational patents.
However, investors should note the challenge of translating strong IP positions into commercial success. While CureVac possesses valuable intellectual property, their ability to monetize these assets through successful product development or licensing agreements will ultimately determine shareholder value. The current market valuation suggests investors remain skeptical about near-term commercialization prospects, despite the company's robust patent position.
CureVac among global top 100 most fast-paced innovators for third consecutive year in acknowledgment of its innovative strength and extensive intellectual property portfolio
The company holds one of the broadest intellectual property portfolios in mRNA technology
TÜBINGEN, GERMANY AND BOSTON, MA / ACCESS Newswire / February 18, 2025 / CureVac N.V. (Nasdaq:CVAC), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), today announced its recognition as a Top 100 Global Innovator in the Innovation Momentum 2025 report by LexisNexis®. The renowned LexisNexis "Top 100 Global Innovators list" recognized the 100 most dynamic companies worldwide that are driving innovation across their businesses and industries, based on the quality and advancement of their patent portfolios. CureVac has previously received the recognition twice, in 2023 and 2024.
"CureVac's extensive intellectual property portfolio, built on more than two decades of pioneering work in mRNA science, continues to rank among the most influential and dynamic in the field," said Dr. Alexander Zehnder, Chief Executive Officer of CureVac. "Being recognized for the third consecutive year by LexisNexis as one of the world's Top 100 Global Innovators underscores not only the enduring strength of our patent estate but also the ongoing value of our scientific contributions to the future of medicine. Our foundational innovations have played a vital role in shaping the mRNA field and supporting global public health, and we remain committed to advancing the boundaries of this transformative technology."
The Innovation Momentum methodology identifies companies with patents that outperform their peers based on the potential to lead to further inventions and the scope of market protection, rewarding companies with small but high-quality portfolios or those with more extensive holdings that are well-maintained over time. Innovation Momentum builds on the Patent Asset Index, a unique patent evaluation methodology featured in the analytics platform LexisNexis® PatentSight®.
As the pioneer of mRNA therapeutics, CureVac developed proprietary foundational technologies over the last 25 years related to mRNA design, delivery and manufacturing, which materially contributed to the development of safe and efficacious COVID-19 vaccines as well as many other advances. Today, the company holds one of the broadest and most diversified patent portfolios in the field with approximately 1,000 issued patents covering mRNA technology, manufacturing and mRNA-based vaccines and therapies.
About CureVac
CureVac (Nasdaq:CVAC) is a pioneering multinational biotech company founded in 2000 to advance the field of messenger RNA (mRNA) technology for application in human medicine. In more than two decades of developing, optimizing, and manufacturing this versatile biological molecule for medical purposes, CureVac has introduced and refined key underlying technologies that were essential to the production of mRNA vaccines against COVID-19, and is currently laying the groundwork for application of mRNA in new therapeutic areas of major unmet need. CureVac is leveraging mRNA technology, combined with advanced omics and computational tools, to design and develop off-the-shelf and personalized cancer vaccine product candidates. It also develops programs in prophylactic vaccines and in treatments that enable the human body to produce its own therapeutic proteins. Headquartered in Tübingen, Germany, CureVac also operates sites in the Netherlands, Belgium, Switzerland, and the U.S. Further information can be found at www.curevac.com.
CureVac Media and Investor Relations Contact
Dr. Sarah Fakih, Vice President Corporate Communications and Investor Relations
CureVac, Tübingen, Germany
T: +49 7071 9883-1298
M: +49 160 90 496949
sarah.fakih@curevac.com
Forward-Looking Statements of CureVac
This press release contains statements that constitute "forward looking statements" as that term is defined in the United States Private Securities Litigation Reform Act of 1995, including statements that express the opinions, expectations, beliefs, plans, objectives, assumptions or projections of CureVac N.V. and/or its wholly owned subsidiaries CureVac SE, CureVac Manufacturing GmbH, CureVac Inc., CureVac Swiss AG, CureVac Corporate Services GmbH, CureVac Belgium SA and CureVac Netherlands B.V. (the "company") regarding future events or future results, in contrast with statements that reflect historical facts. Examples include discussion of the potential efficacy of the company's vaccine and treatment candidates and the company's strategies, financing plans, cash runway expectations, the timing and impact of restructuring, growth opportunities and market growth. In some cases, you can identify such forward-looking statements by terminology such as "anticipate," "intend," "believe," "estimate," "plan," "seek," "project," "expect," "may," "will," "would," "could," "potential," "intend," or "should," the negative of these terms or similar expressions. Forward-looking statements are based on management's current beliefs and assumptions and on information currently available to the company. However, these forward-looking statements are not a guarantee of the company's performance, and you should not place undue reliance on such statements. Forward-looking statements are subject to many risks, uncertainties and other variable circumstances, including negative worldwide economic conditions and ongoing instability and volatility in the worldwide financial markets, ability to obtain funding, ability to conduct current and future preclinical studies and clinical trials, the timing, expense and uncertainty of regulatory approval, reliance on third parties and collaboration partners, ability to commercialize products, ability to manufacture any products, possible changes in current and proposed legislation, regulations and governmental policies, pressures from increasing competition and consolidation in the company's industry, the effects of the COVID-19 pandemic on the company's business and results of operations, ability to manage growth, reliance on key personnel, reliance on intellectual property protection, ability to provide for patient safety, fluctuations of operating results due to the effect of exchange rates, delays in litigation proceedings, different judicial outcomes or other factors. Such risks and uncertainties may cause the statements to be inaccurate and readers are cautioned not to place undue reliance on such statements. Many of these risks are outside of the company's control and could cause its actual results to differ materially from those it thought would occur. The forward-looking statements included in this press release are made only as of the date hereof. The company does not undertake, and specifically declines, any obligation to update any such statements or to publicly announce the results of any revisions to any such statements to reflect future events or developments, except as required by law.
For further information, please reference the company's reports and documents filed with the U.S. Securities and Exchange Commission (the "SEC"). You may get these documents by visiting EDGAR on the SEC website at www.sec.gov.
SOURCE: CureVac
View the original press release on ACCESS Newswire
FAQ
How many patents does CureVac (CVAC) currently hold in mRNA technology?
What recognition did CureVac (CVAC) receive from LexisNexis in 2025?
How long has CureVac (CVAC) been developing mRNA technology?
What areas do CureVac's (CVAC) patents cover in mRNA technology?
